Authors

Latest:

Dr. Juergens on the IND.226 Trial in Advanced Non-Squamous NSCLC

Rosalyn Juergens, MD, PhD, assistant professor, Department of Oncology, Division of Medical Oncology, McMaster University, discusses the results of the IND.226 trial, in an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.

Rosandra N. Kaplan, MD

Latest:

Dr. Kaplan on the Treatment of Pediatric Patients With Sarcoma

Rosandra N. Kaplan, MD, investigator, Pediatric Oncology Branch, Head, Tumor Microenvironment Section, National Cancer Institute, discusses the treatment of pediatric patients with sarcoma.

Rosario Garcia Campelo, MD

Latest:

Dr. Campelo on the Rationale for the ALTA-1L Trial

Rosario Garcia Campelo, MD, medical oncologist, University Hospital Caruna, talks about a randomized trial assessing health-related quality of life in patients with ALK-positive non–small cell lung cancer patients who were treated with brigatinib versus crizotinib.

Rose K. Lai, MD

Latest:

Dr. Lai on Risk Factors Associated With Glioma

Rose K. Lai, MD, clinical associate professor of Neurology, University of Southern California, discusses results of the Glioma International Case Control study.

Ross Camidge, MD, PhD, University of Colorado Cancer Center

Ross Perko, MD

Latest:

Lessons on Patient Care Learned at Home

This fellow shares the insights heâ€™s gained from his wife, a pediatric oncology nurse, and how they help in the care he provides.

Rowan Chlebowski, MD, PhD

Latest:

Dr. Chlebowski on How Weight Loss Improves TNBC Survival

As few as five pounds of weight loss can make a significant difference for patients with triple-negative breast cancer, says Rowan Chlebowski, MD, PhD, a medical oncologist at the Los Angeles Biomedical Research Institute at the Harbor-UCLA Medical Center.

Rowan T. Chlebowski, MD, PhD

Latest:

Breast Cancer Chemoprevention: Targeting the Estrogen Receptor

New strategies to increase the uptake of these proven breast cancer risk-reduction interventions in general clinical practice are needed.

Rowena N. Schwartz, PharmD, BCOP

Latest:

Venous Thromboembolism and Cancer: An Opportunity for Pharmacists to Optimize Care

The management of venous thromboembolism (VTE) disorders is well described in the literature, and comprehensive guidelines are available from the American College of Chest Physicians.

Roxanne Nelson

Latest:

Clinics Strive to Improve Revenue and Patient Care Amid a Growing "Cost Consciousness"

Growing awareness is prompting a revolution in vigilance and attention to detail that has significance both for the quality of care and financial health of practices.

Roy A. Beveridge, MD

Latest:

Understanding the Implications of Mandatory Vendor Imposition in Oncology

The rising costs of healthcare have caused payers to analyze spending and take measures to contain costs.

Roy Chemaly, MD, MPH, MD Anderson Cancer Center

Roy Chemaly, MD, The University of Texas MD Anderson Cancer Center

Roy Decker MD, PhD

Latest:

Dr. Decker on Pembrolizumab With Concurrent Chemoradiotherapy in Inoperable Locally Advanced NSCLC

Roy H. Decker, MD, PhD, discusses the use of pembrolizumab with concurrent chemoradiotherapy in patients with inoperable, locally advanced non–small cell lung cancer.

Roy Herbst, MD

Latest:

Dr. Herbst on Considerations for Frontline Immunotherapy in NSCLC

Roy S. Herbst, MD, PhD, discusses considerations for frontline immunotherapy in non–small cell lung cancer.

Roy Herbst, MD, PhD, Yale Cancer Center

Latest:

Perioperative Approaches to NSCLC

Drs Chaitali Nangia and Sandip P. Patel debate between best treatment approaches for patients with non–small cell lung cancer in the perioperative setting.

Roy Herbst, MD, Yale School of Medicine

Roy S. Herbst, MD, PhD

Latest:

EGFR mNSCLC: Future Directions

Panelists discuss how despite significant advances in EGFR-targeted therapy, critical unmet needs persist in EGFR-positive non–small cell lung cancer (NSCLC), including the need for better strategies to combat resistance mechanisms, more effective treatments for brain metastases, improved options for uncommon EGFR mutations, and the development of biomarker-driven approaches to optimize sequencing of available therapies.

Roy S. Herbst, MD, PhD, Yale

Roy S. Herbst, MD, PhD, Yale Cancer Center

Latest:

Immunotherapy for NSCLC: Clinical Pearls

Final takeaways from ASCO 2021 and the use of immunotherapy to treat various types of patients with non–small cell lung cancer.